Literature DB >> 7644122

GABAB antagonists diminish the inhibitory gating of auditory response in the rat hippocampus.

K M Hershman1, R Freedman, P C Bickford.   

Abstract

Auditory evoked responses recorded from the CA3 region of the rat hippocampus show diminished response to repeated stimuli, suggesting the activity of an inhibitory gating mechanism. The effects on this putative gating mechanism of two GABAB receptor antagonists, CGP35348 and CGP46381, were characterized in a conditioning testing paradigm. Both compounds, administered intracerebroventricularly, antagonized the suppression of response to the test stimulus. The results are consistent with the hypothesis that this inhibitory gating of response involves GABAB receptors, which may control the release of glutamate from excitatory pathways in the hippocampus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7644122     DOI: 10.1016/0304-3940(95)11523-y

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

Review 1.  Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.

Authors:  Diogo R Lara
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

2.  Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.

Authors:  R Freedman; H Coon; M Myles-Worsley; A Orr-Urtreger; A Olincy; A Davis; M Polymeropoulos; J Holik; J Hopkins; M Hoff; J Rosenthal; M C Waldo; F Reimherr; P Wender; J Yaw; D A Young; C R Breese; C Adams; D Patterson; L E Adler; L Kruglyak; S Leonard; W Byerley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  GABA(B) receptor blockade in the hippocampus affects sensory and sensorimotor gating in Long-Evans rats.

Authors:  Jingyi Ma; L Stan Leung
Journal:  Psychopharmacology (Berl)       Date:  2011-04-12       Impact factor: 4.530

Review 4.  Measuring GABAergic inhibitory activity with TMS-EEG and its potential clinical application for chronic pain.

Authors:  Mera S Barr; Faranak Farzan; Karen D Davis; Paul B Fitzgerald; Zafiris J Daskalakis
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-29       Impact factor: 4.147

Review 5.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

6.  Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating.

Authors:  Richard J Radek; Holly M Miner; Natalie A Bratcher; Michael W Decker; Murali Gopalakrishnan; Robert S Bitner
Journal:  Psychopharmacology (Berl)       Date:  2006-05-06       Impact factor: 4.530

Review 7.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

8.  Schizophrenia diagnosis and anterior hippocampal volume make separate contributions to sensory gating.

Authors:  Robert J Thoma; Faith M Hanlon; Helen Petropoulos; Gregory A Miller; Sandra N Moses; Ashley Smith; Lauren Parks; S Laura Lundy; Natalie M Sanchez; Aaron Jones; Mingxiong Huang; Michael P Weisend; Jose M Cañive
Journal:  Psychophysiology       Date:  2008-09-24       Impact factor: 4.016

Review 9.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

10.  Inhibitory control of sensory gating in a computer model of the CA3 region of the hippocampus.

Authors:  Karen A Moxon; Greg A Gerhardt; Maria Gulinello; Lawrence E Adler
Journal:  Biol Cybern       Date:  2003-04       Impact factor: 2.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.